|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 985.24 Million
|
|
Market Size (2030)
|
USD 1607.87 Million
|
|
CAGR (2025-2030)
|
8.48%
|
|
Fastest Growing Segment
|
Skin Cancers
|
|
Largest Market
|
Mid-West
|
Market Overview
The United States Veterinary Oncology
Diagnostics Market was valued at USD 985.24 Million in 2024 and is expected to
reach USD 1607.87 Million by 2030 with a CAGR of 8.48%. The United
States Veterinary Oncology Diagnostics Market is experiencing robust growth due
to the increasing awareness among pet owners about the importance of early
cancer detection. As pet owners become more proactive about their pets’ health,
the demand for advanced diagnostic tests for various cancers, including skin
cancer, lymphoma, and other internal tumors, is rising. This growing awareness
is being supported by veterinary professionals who emphasize the need for
regular screenings, particularly for aging pets or those with a family history
of cancer. The availability of advanced diagnostic tools, including molecular
diagnostics, advanced imaging, and biomarker testing, has significantly
contributed to the market's expansion. These technologies allow for more
precise and earlier detection, which improves the prognosis and treatment
options for affected animals.
A key trend driving the market is the increasing
adoption of personalized treatment plans for pets diagnosed with cancer.
Veterinary oncology is evolving to include more tailored approaches that cater
to the specific needs of each pet, leveraging advancements in diagnostic
technology to determine the most effective course of treatment. The rise in
demand for minimally invasive diagnostic procedures, which offer faster
recovery times and reduced risks compared to traditional methods, is also
fueling market growth. The introduction of AI-based diagnostic systems is
another emerging trend, offering quicker and more accurate results, further
enhancing early detection capabilities. These innovations are not only
improving diagnostic outcomes but also providing pet owners with greater peace
of mind regarding their pets' health.
Despite its growth potential, the United States
Veterinary Oncology Diagnostics Market faces several challenges. One of the
primary hurdles is the high cost of advanced diagnostic tests and treatments,
which can limit accessibility for many pet owners. While some pet insurance
plans cover oncology diagnostics, the cost of specialized care remains a
barrier for a significant portion of the market. There is also a shortage of
veterinary oncologists and trained diagnostic professionals, which can result
in longer wait times for diagnosis and treatment. Furthermore, the regulatory
complexities associated with the approval of new diagnostic technologies may
slow down the pace of innovation and market entry for newer solutions. The
limited availability of specialized oncology diagnostic services, particularly
in rural or underserved areas, poses another challenge. Overcoming these
barriers will be essential for the market to realize its full potential in the
coming years.
Key Market Drivers
Rising
Prevalence of Cancer in Pets
The rising prevalence of cancer in pets is a
significant driver for the United States Veterinary Oncology Diagnostics
Market. Approximately 1 in 4 dogs will develop neoplasia at some stage in
their life, and nearly half of dogs over the age of 10 will be diagnosed with
cancer. In 2023, an estimated 4.2 million dogs were diagnosed with cancer in
the United States, equating to a rate of about 53 cases per 1,000 dogs
annually. This high incidence rate underscores the growing need for
advanced diagnostic tools capable of early and accurate detection.
Early detection is crucial for improving treatment
outcomes and survival rates in pets. Advanced diagnostic technologies, such as
molecular diagnostics, imaging tools, and blood tests, enable veterinarians to
identify cancer at its earliest stages, often before visible symptoms appear.
This proactive approach allows for timely intervention, which can significantly
enhance the effectiveness of treatment plans.
As awareness of cancer's prevalence among pets
increases, both veterinarians and pet owners are becoming more proactive about
seeking diagnostic testing. Many pet owners now include cancer screenings as
part of routine veterinary visits, contributing to a steady increase in the
demand for oncology diagnostics. The rising number of specialized veterinary
oncology clinics and the availability of cutting-edge diagnostic services are
further fueling market growth. This growing focus on cancer detection, combined
with the increasing prevalence of cancer in pets, is expected to continue
driving the veterinary oncology diagnostics market in the U.S. through the
forecast period.
Advancements
in Diagnostic Technology
Advancements in diagnostic technology are a
significant driver of growth in the United States Veterinary Oncology
Diagnostics Market. Recent innovations in molecular diagnostics, imaging
technologies, and biomarkers are transforming the way veterinary professionals
detect and diagnose cancer in pets. For example, improvements in imaging
techniques, such as MRI and CT scans, enable more detailed and accurate
visualization of tumors, even in the early stages. These technologies help
veterinarians identify cancerous growths that might otherwise go undetected
using traditional methods. Additionally, the integration of artificial
intelligence (AI) and machine learning (ML) into diagnostic tools has
revolutionized image analysis, allowing for faster and more precise
interpretation of complex data, leading to quicker diagnoses.
Molecular diagnostics, including liquid biopsy and
genetic testing, have become increasingly sophisticated, enabling the detection
of cancer-related genetic mutations or specific biomarkers present in a pet’s
blood or urine. This non-invasive method not only increases the accuracy of
diagnoses but also reduces the discomfort and stress associated with
traditional biopsy procedures. Advances in next-generation sequencing (NGS)
technologies have made it possible to identify mutations and alterations in a pet’s
DNA associated with various types of cancer, further enhancing early detection
capabilities.
These technological advancements are improving
diagnostic precision, increasing the effectiveness of cancer treatments, and
providing more treatment options. As a result, the demand for advanced
veterinary oncology diagnostics is rising. Veterinarians are increasingly
adopting these cutting-edge tools, contributing to the market's growth and
making veterinary oncology diagnostics more accessible and reliable for pet
owners. Such innovations promise a future where earlier detection and
personalized treatment plans become the standard in veterinary oncology.
Advances
in Pet Health Insurance
Advances in pet health insurance are significantly
influencing the United States Veterinary Oncology Diagnostics Market by
enhancing accessibility and affordability of cancer detection and treatment for
pets. As of 2023, pet expenditures in the U.S. reached $102.8 billion,
reflecting a 77.9% increase from 2013. This surge in spending
underscores the growing prioritization of pet health among owners. The
expansion of pet health insurance coverage, including policies that encompass
cancer screenings, diagnostic tests, and treatments, has been instrumental in
this trend. Comprehensive pet insurance plans often cover diagnostic procedures
such as blood tests, urinalyses, X-rays, and ultrasounds, which are essential
for early cancer detection. This financial support encourages pet owners to
seek timely veterinary care, leading to earlier diagnoses and improved
treatment outcomes.
Furthermore, legislative efforts,
such as the introduction of the Pet Insurance Model Act by the National
Association of Insurance Commissioners in 2022, aim to establish regulatory
frameworks that enhance consumer protection and standardize coverage, thereby
fostering trust and encouraging broader adoption of pet insurance. These
developments collectively contribute to the growth of the veterinary oncology
diagnostics market by making advanced diagnostic services more accessible and
financially feasible for pet owners.
Download Free Sample Report
Key Market Challenges
Limited
Access to Specialized Veterinary Oncologists
Limited access to specialized veterinary oncologists
is a significant challenge facing the United States Veterinary Oncology
Diagnostics Market. While large urban areas may have veterinary oncology
specialists, rural regions often lack such expertise, creating a disparity in
healthcare accessibility. This shortage can delay cancer diagnosis and
treatment for pets, potentially reducing survival rates and limiting the
effectiveness of available therapies. Pet owners in underserved areas may have
to travel long distances to reach specialized care centers, which can be both
costly and time-consuming. In some cases, they may opt not to pursue
specialized care at all due to these barriers, resulting in missed
opportunities for early cancer detection and treatment.
The growing demand for specialized veterinary care,
including oncology services, places additional strain on the existing network
of oncologists. With a relatively small pool of trained veterinary oncologists
in the United States, many clinics are unable to provide specialized care,
leading to a bottleneck in the diagnostic process. This shortage is further
exacerbated by the increasing awareness of cancer in pets, which has resulted
in more pet owners seeking specialized diagnostic services. As the field of
veterinary oncology grows, so does the need for more professionals with
expertise in this area to meet the rising demand for cancer diagnostics and
treatments.
The limited number of specialized oncologists also
affects the adoption of advanced diagnostic technologies. Veterinary clinics
and hospitals that lack oncology specialists may not prioritize investing in
cutting-edge diagnostic tools, limiting the overall growth of the market. Until
the access to specialized veterinary oncologists improves, the diagnostic
market will continue to face constraints, affecting both treatment outcomes and
the expansion of advanced diagnostic services.
Regulatory
Challenges and Long Approval Times
Regulatory challenges and long approval times
represent significant obstacles for the United States Veterinary Oncology
Diagnostics Market. The approval process for new diagnostic technologies in
veterinary oncology is complex and time-consuming. Diagnostic tools must
undergo extensive testing to meet the regulatory standards set by the U.S. Food
and Drug Administration (FDA) or other regulatory bodies. This process ensures
the safety, efficacy, and reliability of products before they can be introduced
to the market. However, the lengthy approval timeline can delay the
availability of innovative diagnostic solutions, limiting their potential to
impact the market and pet healthcare.
These regulatory delays can be especially challenging
for small and medium-sized companies that may not have the resources to
expedite the approval process or navigate the regulatory environment
efficiently. In addition, the evolving nature of veterinary oncology, with the
introduction of cutting-edge technologies such as artificial intelligence (AI)
and molecular diagnostics, presents new challenges for regulators who need to
adapt their frameworks to accommodate these innovations. As regulatory agencies
work to establish clear guidelines for emerging technologies, veterinary
oncology companies may face uncertainty about the approval process, which can
further hinder product development and market entry.
The stringent regulatory requirements not only prolong
the approval time but also add to the overall costs for manufacturers. This
increases the financial burden for companies trying to bring new diagnostic
tools to market, potentially leading to delays in the adoption of life-saving
technologies. Regulatory hurdles may also result in limited availability of
certain diagnostic tools in veterinary practices, especially in areas where
resources are constrained, preventing a timely diagnosis for pets in need of
cancer screening and treatment.
Key Market Trends
Shift
Toward Non-Invasive Diagnostics
The United States Veterinary Oncology Diagnostics
Market is experiencing a notable shift towards non-invasive diagnostic methods,
driven by the demand for less stressful and more accessible procedures for
pets. Traditional diagnostic methods, such as biopsy and surgical procedures,
can be invasive, costly, and uncomfortable for animals, leading to an increased
interest in alternatives that minimize physical discomfort and risk.
Non-invasive techniques, such as liquid biopsies, blood tests, and advanced imaging
technologies like MRI and ultrasound, have gained traction due to their ability
to accurately detect cancer with minimal intervention.
One of the key drivers behind this trend is the
growing awareness among pet owners and veterinarians of the benefits
non-invasive diagnostics offer in terms of ease, accuracy, and faster results.
For example, liquid biopsy allows for the detection of cancer-related
biomarkers in the bloodstream, enabling early detection without the need for
surgical tissue samples. These methods not only reduce the stress on animals
but also make it easier to perform regular monitoring, which is critical for
early-stage cancer detection and ongoing disease management.
The technological advancements in non-invasive
diagnostic tools have further fueled this trend. High-resolution imaging and
molecular testing have improved significantly, allowing veterinarians to detect
tumors and cancerous cells with greater precision. These developments have made
it possible to diagnose cancers in their early stages, when treatment options
are most effective. As a result, the shift toward non-invasive diagnostics is
expected to grow as pet owners and veterinary clinics increasingly prioritize
procedures that offer convenience, accuracy, and enhanced patient comfort,
driving the market forward in the forecast period.
Adoption
of Molecular Diagnostics
The United States Veterinary Oncology Diagnostics
Market is experiencing a significant shift toward the adoption of molecular
diagnostics, reflecting advancements in veterinary medicine and a growing
emphasis on personalized care for pets. Molecular diagnostic techniques, such
as polymerase chain reaction (PCR) and next-generation sequencing (NGS), enable
veterinarians to detect genetic mutations and molecular markers associated with
various cancers in dogs and cats. These methods allow for earlier detection,
more accurate diagnoses, and the development of tailored treatment plans,
thereby improving patient outcomes.
A notable trend is the increasing integration of
molecular diagnostics into routine veterinary practice. For instance, the
National Institutes of Health (NIH) reported that approximately 3.3 billion in
vitro diagnostic (IVD) tests are performed annually in the U.S., encompassing a
wide range of applications, including veterinary diagnostics. This
indicates a substantial volume of diagnostic tests being conducted,
highlighting the growing reliance on advanced diagnostic technologies in
veterinary medicine.
Furthermore, the U.S. Food and Drug Administration
(FDA) has been actively involved in regulating and facilitating the development
of diagnostic tests, including those used in veterinary oncology. The FDA's
oversight ensures that molecular diagnostic tests meet safety and efficacy
standards, thereby fostering confidence among veterinary professionals and pet
owners in the reliability of these diagnostic tools.
The adoption of molecular diagnostics in veterinary
oncology is not only enhancing the accuracy of cancer detection but also
contributing to the advancement of personalized medicine for pets. By
identifying specific genetic alterations, veterinarians can customize treatment
strategies to the individual needs of each animal, leading to more effective
and targeted therapies. This trend is expected to continue growing, driven by
technological advancements, regulatory support, and an increasing demand for high-quality
veterinary care.
Segmental Insights
Animal
Type Insights
Based
on the Animal Type, Canine emerged as the dominant segment in the United
States Veterinary Oncology Diagnostics Market in 2024. This is due to the
high incidence of cancer in dogs compared to other companion animals. Dogs are
more prone to developing various types of tumors, including lymphoma, mast cell
tumors, and osteosarcoma, which has led to a growing demand for early and
accurate oncology diagnostics within this segment. Pet owners are increasingly
aware of the signs and risks of cancer in dogs, resulting in more frequent
veterinary visits and screening tests. Veterinarians are also prioritizing
oncology diagnostics in canine patients due to advancements in diagnostic tools
such as fine-needle aspiration cytology, biopsy analysis, genetic testing, and
biomarker-based screening methods. The strong emotional bond between pet owners
and their dogs drives investment in preventive and personalized veterinary
care, further boosting the demand for canine-specific oncology diagnostics.
Test
Type Insights
Based on the Test Type, Biopsy emerged as the
dominant segment in the
United States Veterinary Oncology Diagnostics Market in 2024. This
is due to its critical role in providing definitive cancer diagnoses in
animals. Biopsies, whether incisional or excisional, allow for direct examination
of tissue samples, enabling pathologists to determine tumor type, grade, and
malignancy. This level of diagnostic precision is essential for creating
effective, targeted treatment plans and improving patient outcomes. As cancer
cases in companion animals continue to rise, veterinarians are increasingly
relying on biopsy procedures to confirm diagnoses and differentiate between
benign and malignant growths. The growing availability of advanced
histopathological analysis and immunohistochemistry techniques has also
strengthened the diagnostic capabilities of biopsies, further reinforcing their
importance in veterinary oncology.
Download Free Sample Report
Regional Insights
The Mid-West region
emerged as the dominant region in the United States Veterinary
Oncology Diagnostics Market in 2024. This is due to its strong network of
veterinary research institutions, specialty animal hospitals, and diagnostic
laboratories. States such as Illinois, Minnesota, and Ohio host some of the
country’s most advanced veterinary colleges and oncology research centers,
which play a critical role in driving the adoption of innovative cancer
diagnostic tools. The region’s well-developed infrastructure supports the
integration of advanced diagnostic technologies, including molecular
diagnostics, biomarker testing, and histopathology, enabling early and accurate
detection of cancer in pets. Additionally, the Mid-West has a high pet
ownership rate, and growing awareness among pet parents about the importance of
early cancer detection is leading to increased demand for oncology diagnostics.
The presence of key veterinary diagnostic service providers in the region
further contributes to market leadership, as they continuously enhance testing
capabilities and expand access to cutting-edge cancer diagnostics.
Recent Developments
- In January 2025, IDEXX Laboratories introduced IDEXX
Cancer Dx, a cost-effective blood test designed for the early detection of
canine lymphoma. Set to be available in the U.S. and Canada by March 2025, the
test delivers results within 2–3 days and can be incorporated into routine
wellness screenings, enabling earlier diagnosis and intervention.
- In December 2024, Torigen Pharmaceuticals launched
Torigen Specialty Pathology, a rapid cancer diagnostics service for pets. With
expert-reviewed results delivered within 3–5 days and actionable insights, the
service helps veterinarians make timely treatment decisions and complements
Torigen’s personalized cancer immunotherapy offerings.
- In April 2024, VolitionRx Limited announced
the in-clinic availability of its Nu.Q Vet Cancer Test for veterinarians across
the U.S. and Europe through Antech. The test, running on the Element i+
Analyzer, offers a fast, accurate, and cost-effective cancer screening solution
for high-risk and older dogs, delivering results in approximately six minutes
at the point of care.
- In December 2023, a study published in
the American Journal of Veterinary Research confirmed that the OncoK9 liquid
biopsy test by PetDx can be used to monitor cancer recurrence and residual
disease in dogs across multiple cancer types. Utilizing next-generation
sequencing (NGS) technology, the test analyzes cell-free DNA in blood samples.
The study included over 50 dogs with 12 different cancer types, monitored for
up to one year following surgery. Results demonstrate OncoK9's potential for
ongoing cancer surveillance in veterinary care.
- In June 2023, IDEXX Laboratories, Inc. launched the
first veterinary diagnostic test for detecting kidney injury in cats and dogs.
The IDEXX Cystatin B Test, aimed at improving diagnosis of often subtle or
nonspecific kidney issues, will be included in renal health panels and is
expected to impact around two million patient visits annually.
Key Market Players
- Zoetis
Inc.
- Neogen
Corporation
- Antech
Diagnostics, Inc.
- IDEXX
Laboratories, Inc.
- Embark
Veterinary, Inc.
- Boehringer
Ingelheim Animal Health USA Inc.
- Arizona
Veterinary Oncology
- Varian
Medical Systems, Inc.
- Merck
& Co., Inc.
- Oncotect,
Inc.
|
By Animal Type
|
By Test Type
|
By Cancer Type
|
By End User
|
By Region
|
|
|
- Blood Tests
- Biopsy
- Genome testing
- Endoscopy
- Urinalysis
- Imaging
|
- Lymphoma
- Sarcomas
- Mammary Gland Tumors
- Skin Cancers
- Others
|
- Reference Laboratories
- Veterinary Hospitals and Clinics
- Others
|
- North-East
- Mid-West
- West
- South
|
Report Scope:
In this report, the United
States Veterinary Oncology Diagnostics Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- United
States Veterinary Oncology Diagnostics Market, By Animal Type:
o
Canine
o
Feline
o
Others
- United
States Veterinary Oncology Diagnostics Market, By Test Type:
o
Blood
Tests
o
Biopsy
o
Genome
testing
o
Endoscopy
o
Urinalysis
o
Imaging
- United
States Veterinary Oncology Diagnostics Market, By Cancer Type:
o
Lymphoma
o
Sarcomas
o
Mammary
Gland Tumors
o
Skin
Cancers
o
Others
- United
States Veterinary Oncology Diagnostics Market, By End User:
o
Reference
Laboratories
o
Veterinary
Hospitals and Clinics
o
Others
- United
States Veterinary Oncology Diagnostics Market, By Region:
o
North-East
o
Mid-West
o
West
o South
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the United States Veterinary
Oncology Diagnostics Market.
Available Customizations:
United States Veterinary Oncology Diagnostics Market report with the given market data,
TechSci Research offers customizations according to a company's specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
United States Veterinary Oncology Diagnostics Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at sales@techsciresearch.com